tradingkey.logo

Thermo Fisher Q4 revenue, profit beat estimates

ReutersJan 29, 2026 11:08 AM


Overview

  • Science services leader's Q4 revenue grew 7%, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company completed acquisitions to enhance bioproduction and clinical trial capabilities


Outlook

  • Company will provide 2026 financial guidance during its earnings conference call


Result Drivers

  • INNOVATIVE PRODUCT LAUNCHES - Co launched new products like Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, contributing to Q4 growth

  • STRATEGIC COLLABORATIONS - Co's collaboration with OpenAI and expansion of bioprocess design centers in Asia supported growth

  • CAPITAL DEPLOYMENT - Co's acquisition of Clario and other investments enhanced capabilities, driving Q4 results


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$12.22 bln

$11.95 bln (18 Analysts)

Q4 Adjusted EPS

Beat

$6.57

$6.45 (20 Analysts)

Q4 EPS

$5.21

Q4 Adjusted Net Income

Beat

$2.48 bln

$2.43 bln (15 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Thermo Fisher Scientific Inc is $652.00, about 7.2% above its January 28 closing price of $608.02

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBw1Q3rd4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI